rfj,
DEPO has marketed products (Glumetza and Proquin) that are not blockbusters but do make money. The GERD compound will further validate AcuForm as a viable DD technology, that will be bigger than a baclofen compound!
Again, if they are able to hit a sweet pricing point between generic Gabapentin and Pregabalin and have efficacy trending towards Pregabalin then they will pick up some serious sales.
HS
Market Data 
Markets 
AI
